Welcome to our dedicated page for Precision Optics news (Ticker: POCI), a resource for investors and traders seeking the latest updates and insights on Precision Optics stock.
Precision Optics Corporation, Inc. reports recurring business developments in advanced optical instruments for the medical and defense/aerospace industries. The company designs, develops and manufactures custom optical medical devices, endoscopes, endocouplers and related optical assemblies, with news frequently covering single-use endoscopy programs and customer production orders.
Updates for POCI also include product-development work for aerospace and defense applications, including small-diameter borescope systems used in jet-engine inspection. Company announcements commonly address fiscal-period operating results, conference calls, customer program activity, backlog and pipeline commentary, and capital-structure actions involving its Nasdaq-listed common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Precision Optics Corporation (NASDAQ: POCI) announced its participation in the Planet MicroCap Showcase: VEGAS 2023, taking place on April 26-27, 2023. Dr. Joe Forkey, the CEO, will present at the event, with a webcast of the presentation available at 7:00 PM ET on April 26. The presentation will also be archived for later viewing. In addition, the management team will hold one-on-one meetings at the conference venue in Las Vegas. For those interested in booking a meeting, they can contact the event organizers or email POCI directly.
Founded in 1982, Precision Optics specializes in advanced optical instruments for medical and defense applications. The company focuses on micro-optics and 3D imaging technologies, supporting minimally invasive surgeries and surgical robotic systems.
Precision Optics Corporation (NASDAQ: POCI), based in Gardner, Massachusetts, has announced a significant development order worth approximately $1.3 million for a next-generation urological endoscopy program. This order comes from a well-known medical device company and represents a strategic shift for Precision Optics, moving from a component supplier to a developer of complete endoscope imaging systems. The product development will be conducted in collaboration with Lighthouse Imaging, showcasing the company’s expertise in micro-optics, medical systems, and digital imaging. The agreement's completion is anticipated within the next 12 months, paving the way for potential future contracts.
CEO Joe Forkey emphasized that this agreement is a significant opportunity to enhance their role in medical imaging, supporting the increasing demand for integrated optics and electronics in next-generation products.
Precision Optics Corporation (NASDAQ: POCI) has named Mahesh Lawande as its new Chief Operating Officer, effective April 24, 2023. This leadership change arises from the company's significant growth, with revenues increasing by 47% in fiscal 2022 and 76% in the first half of fiscal 2023, largely due to acquisitions. Lawande brings over 25 years of experience in medical device and aerospace/defense manufacturing, having held key roles at Siemens and Draeger. His appointment aims to enhance the company's operational capabilities to manage increasing complexity and drive continued growth and profitability. This strategic move signifies Precision Optics' commitment to scaling its operations amidst rapid expansion.
Precision Optics Corporation (NASDAQ: POCI) reported a significant 51% increase in revenue for Q2 fiscal 2023, reaching $5.89 million, compared to $3.90 million in the same quarter last year. A one-time sale contributed $600,000 to this figure. The gross margin improved to 46% from 29% year-over-year. The company achieved a net income of $634,420, a turnaround from a net loss of $(507,013) last year. Adjusted EBITDA was $993,449, up from $(72,456), indicating improved profitability. Key orders received included $750,000 from a medical device company and $2.6 million from a defense contractor.
Precision Optics Corporation (NASDAQ: POCI) announced a production and technology license agreement with a major global medical device company on Feb. 13, 2023. This agreement grants the customer exclusive rights to certain POCI intellectual property in the ophthalmic industry, following four years of collaborative product development. POCI received a one-time payment of $600,000 for these rights. Initial production is set for late-2023, with potential royalties for POCI if production is transferred elsewhere. CEO Joe Forkey highlighted that this collaboration is expected to enhance profitability through royalties from single-use medical devices.